Senior Director, Program Management, Oncology at Bristol-Myers Squibb

Princeton, New Jersey, United States

Apply Now

Not SpecifiedCompensation

Senior (5 to 8 years), Expert & Leadership (9+ years)Experience Level

Full TimeJob Type

UnknownVisa

Pharmaceutical, Biotechnology, OncologyIndustries

Requirements

Advanced degree (MS/MBA or Ph.D. desirable) in Life Sciences, Chemical Sciences, Physical Sciences, or other relevant discipline. PMP certification is desirable
15+ years of industry experience, with at least 12 years of direct experience in drug development program / project management
Evidence leading complex global programs across multiple therapy areas (significant experience in Neuroscience or Oncology therapy areas is desired)
Demonstrated long standing experience in all phases of research and drug development, including global regulatory submissions (IND/CTA through NDA/BLA/MAA/JNDA/NDA China) and lifecycle management

Responsibilities

Operate as a strategic partner to the Global Program Lead (GPL), to shape and deliver the Target Product Profile (TPP) and Integrated Development Strategy (IDP) for the assigned asset(s) and associated product indications
Responsible for the rigorous execution of the IDP through matrix or line management of Program Management team members
Serve as the strategic thought partner to the GPL / GPT and core to establish a high performing team environment
Ensure execution of IDP per asset indication, including strong partnership with each sub-team and their leadership to ensure alignment to the TPP/IDP and clear understanding of what they are accountable to deliver
Lead matrixed PM team members to create and maintain integrated cross-functional timelines for each asset indication within approved systems, including scenario plans that actively manage risk, evaluate alternative development strategies as well as acceleration opportunities (or cost savings)
Lead risk management activities at the GPT and ensure risk management activities at the sub-teams and below are performed with timely escalation for high probability x high impact risks. Responsible for delivering the risk management plan, including risk mitigation strategies
Monitor high level direct budget and resource forecasts for assigned asset(s) vs actual spend and effort respectively. Maintains visibility advocacy for the resources required to deliver the IDP
Deliver as a PM SME in discussions with leadership or at governance stage gates
Support GPT annual objective processes and budget planning including annual and long-term processes
Serve as a matrix manager for Program Management resources assigned to the asset
Support their DD PM Group Leads to deliver asset or portfolio content as required
Foster cross-functional thinking to drive and shape program strategy and drive optimal decisions for the broader portfolio
Lead as a change agent and strong representative of the DD PM department vision and ways of working

Skills

Program Management

Target Product Profile

Integrated Development Strategy

Cross-Functional Leadership

Matrix Management

Strategic Planning

Oncology Development

Timeline Management

Bristol-Myers Squibb

Develops and delivers biopharmaceutical medicines

About Bristol-Myers Squibb

Bristol Myers Squibb (BMS) develops and delivers medicines aimed at treating serious diseases, focusing on areas like cancer, autoimmune diseases, and heart conditions. The company conducts extensive research and development to create new drugs, which are sold after receiving regulatory approval. BMS also produces generic drugs, offering affordable alternatives that meet the same quality standards as their branded counterparts. What sets BMS apart from competitors is its dual focus on both innovative and generic medicines, enhancing access to healthcare. The company's goal is to improve patient outcomes while maintaining a commitment to sustainability and corporate responsibility.

New York City, New YorkHeadquarters

1887Year Founded

$33,706.1MTotal Funding

IPOCompany Stage

Biotechnology, HealthcareIndustries

10,001+Employees

Benefits

Flexible Work Hours

Hybrid Work Options

Professional Development Budget

Risks

Increased competition in oncology from emerging biotech firms like ArsenalBio.

BMS's lawsuit over the 340B Drug Pricing Program may lead to regulatory challenges.

Rapid AI and digital tech evolution may pose integration challenges for BMS.

Differentiation

BMS focuses on innovative cancer treatments through collaborations like ArsenalBio for T cell therapies.

The company emphasizes digital health technologies, enhancing clinical trial management and patient engagement.

BMS offers both innovative and generic medicines, increasing affordable healthcare solutions.

Upsides

BMS's partnership with Medidata enhances clinical research processes and patient outcomes.

The collaboration with AI Proteins advances novel miniprotein-based therapeutics, expanding therapeutic modalities.

BMS's global license agreement with BioArctic expands its portfolio in neurodegenerative diseases.

Land your dream remote job 3x faster with AI

Try Jobo Free